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The Helicobacter pylori HP-NAP is a dodecameric protein with a three-dimensional struc-
ture similar to that of bacterioferritins. Originally defined as neutrophil-activating protein,
because of its ability to stimulate neutrophils to produce oxygen radicals, HP-NAP is now
considered a crucial factor in driving the Th1 inflammation in H. pylori infection. This
review summarizes recent studies that have provided a deeper understanding of the pro-
inflammatory and immune modulatory properties of HP-NAP. We first examine the role of
this protein in the H. pylori-associated disease, and then we discuss recent findings that
support the possibility for HP-NAP to become a new tool for therapeutic strategies aimed
at redirecting Th2 into Th1 responses, for example in atopy, vaccinology and cancer
immunotherapy.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Infection of humans with the Gram negative bacterium
Helicobacter pylori is associated with the development of
severe gastroduodenal diseases, including chronic gastritis
and stomach cancer (Goodwin, 1997; Montecucco and
Rappuoli, 2001; Atherton, 2006). A number of virulence
factors produced by the bacterium have been identified.
Among them, a relevant role is played by an oligomeric
protein, termed neutrophil-activating protein (HP-NAP),cter pylori neutrophil
cell adhesion mole-
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. All rights reserved.because of its ability to induce neutrophils to produce
reactive oxygen radicals (Evans et al., 1995).
The napA gene is highly conserved among many
isolates of H. pylori, which may indicate a precise struc-
turally linked function or a lack of immune selection for
diversification of HP-NAP. The atomic structure of HP-NAP
shows a ball-shaped dodecamer formed by four-helix
bundled subunits (17 kDa) with a hollow central part,
similar to the Escherichia coli DNA-binding protein Dps
(Zanotti et al., 2002; Papinutto et al., 2002). Dps proteins
are a family of bacterial stress proteins that are induced
under nutrient limitations. They protect bacterial DNA
from oxidizing radicals generated by the Fenton reaction
and also from various other damaging agents. DNA
protection has a chemical component based on the highly
conserved ferroxidase activity of Dps proteins, and
a physical one based on the capacity of Dps proteins
containing a positively charged N-terminus to bind and
condense DNA (Ceci et al., 2004). HP-NAP does not possess
a positively charged N-terminus but, unlike the other
members of the family, is characterized by a positively
charged protein surface which has been proposed to be
Fig. 1. Model illustrating the pivotal role of HP-NAP in triggering the flogistic
process associated to H. pylori infection and its immunomodulating activity.
HP-NAP, once released from the bacterium in the stomach lumen, crosses
the gastric epithelial lining (1) and the endothelium (2), and stimulates
directly leukocytes to adhere and to extravasate (3). HP-NAP also activates
neutrophils and monocytes to secrete chemokines (4). In this way the
protein, by acting on the recruited cells, could contribute to the maintenance
of the flogistic status. Furthermore, the protein is able to create an IL-12/IL-
23-enriched milieu (5) which is responsible for driving the differentiation of
T helper cells towards the Th1 phenotype (6).
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2007). Interestingly, the same report showed that the DNA
condensation occurs at pH values that correspond to stress
conditions encountered by H. pylori during gastric colo-
nization. Besides these results, several reports concerning
HP-NAP–DNA interaction and protection have been pub-
lished: two independent studies reported that the newly
purified HP-NAP protein as well as that expressed in
Bacillus subtilis do not bind DNA (Wang et al., 2006;
Tonello et al., 1999); another study demonstrated that HP-
NAP, when expressed in E. coli cells, colocalizes with the
nuclear material, suggesting that it can interact with DNA
in vivo (Cooksley et al., 2003). Moreover, Wang et al.
(2006) demonstrated, in a mouse model, that HP-NAP,
although able to induce oxygen radicals’ release, protects
H. pylori from iron-mediated oxidative DNA damage.
HP-NAP can bind up to 500 atoms of iron per dodecamer
and probably iron plays an important role in generation of
the quaternary structure of HP-NAP by promoting stable
dimers that are crucial for the ensuing dodecamer structure
(Kottakis et al., 2008). HP-NAP was originally thought to be
a bacterial ferritin, based on the nucleotide sequence
homology (Evans et al., 1995), with a role in iron binding;
however, other findings revealed that the bacterial protein
is constitutively expressed under iron-depletion, that its
expression is not regulated by the presence or absence of
iron and that it has no part in the metal resistance of H.
pylori (Dundon et al., 2002). Therefore, the role of HP-NAP
for the bacterium remains an elusive issue: one possibility
is that HP-NAP has evolved as a pro-inflammatorymolecule
to induce a moderate state of inflammation, which would
promote H. pylori growth by the release of nutrients from
the inflamed tissue.
HP-NAP is released most likely after cell lysis, and is
capable of crossing the stomach epithelial layer reaching
the underlying tissue and of inducing the activation of the
resident mast cells (Montemurro et al., 2002). These cells
are likely to be the first that encounter HP-NAP and their
activation by the bacterial protein, with granule exocytosis
and release of pro-inflammatory cytokines, is expected to
trigger the inflammatory response. Once accumulated
within the tissue, HP-NAP alone or together with other
bacterial factors would recruit neutrophils and monocytes
from the blood, thus amplifying the flogistic process. The
molecular mechanisms by which HP-NAP exerts such
effects will be discussed in detail in the following two
paragraphs (Fig. 1).
Notably, HP-NAP is a major antigen in the human
immune response; in fact, the majority of the infected
patients have antibodies against this antigen (Satin et al.,
2000). Antibodies against HP-NAP have been documented
in patients with severe gastric disease, such as peptic ulcer
and gastric cancer, suggesting that the presence of anti-HP-
NAP antibodies can be considered as an indicator of
severity of the infection (Long et al., 2009). Considering the
protection conferred by the protein against the subsequent
challenge with H. pylori, HP-NAP has been included in
a very promising vaccinewhich is now in clinical trial (Satin
et al., 2000; Del Giudice et al., 2001; Malfertheiner et al.,
2008). Moreover, interesting results have been recently
reported on an oral recombinant DNA vaccine based ona live attenuated Salmonella typhimurium strain harbouring
the HP-NAP gene (Sun et al., 2006).
Interestingly, the effects on lymphocytes exerted by HP-
NAP are not limited to the activation of T and B cells,
a typical scenario which follows the presentation of an
antigen by the professional antigen presenting cells; HP-
NAP is also able to modulate the effector functions of T
lymphocytes, which are stimulated to differentiate towards
the Th1 phenotype. Such an ability of the protein, that will
be examined in the third part of the review, is probably
responsible for the predominant activation of Th1 cells
occurring in the antrum of H. pylori-infected patients, as it
will be discussed in detail in the fourth part.
The review concludes focusing on the therapeutic
potential of HP-NAP in all the conditions in which an
effective Th1 response is desired, i.e. vaccinology and
cancer immunotherapy.
2. Effects of HP-NAP on neutrophils: recruitment and
activation
H. pylori colonization is typically followed by infiltration
of the gastric mucosa by polymorphonuclear leucocytes,
macrophages and lymphocytes (Dixon et al., 1996; D’Elios
et al., 1997). A strong correlation exists between gastric
infiltration by neutrophils (polymorphonuclear cells;
PMN), mucosal damage and development of duodenal
ulcer disease in H. pylori infections (Davies et al., 1994;
Hamlet et al., 1999). The mechanism underlying the sus-
tained recruitment of PMN to theH. pylori-infected tissue in
vivo is not completely understood; however, compelling
evidence indicates that the neutrophil-activating protein of
H. pylori (HP-NAP) exerts a pivotal role. Until recently, all
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inducing leukocytes to adhere to the endothelium were
conducted in vitro putting PMN and HP-NAP directly in
contact, without considering that in vivo the protein has to
cross the endothelium in order to activate neutrophils
(Evans et al., 1995). A recent report, however, showed that
HP-NAP promoted transendothelial neutrophil migration
also when added into a lower chamber of a transwell
system consisting of a cultured monolayer of human
endothelial cells as barrier between two chambers (Bris-
slert et al., 2005). These findings suggested that HP-NAP
was able to cross the endothelium to contact leukocytes,
but failed to provide direct evidence for the trans-
endothelial passage of HP-NAP. Moreover, it was not
considered that in vivo the under-flow conditions may bias
the effects observed in vitro. The first in vivo evidence that
HP-NAP promotes leukocyte adhesion to the endothelium
and the subsequent extravasationwas obtained by applying
intravital microscopy analysis to rat mesenteric venules
topically exposed to HP-NAP (Polenghi et al., 2007). The
same study showed that HP-NAP is effectively transported
across the endothelium via intracellular route and
a proportion of the protein remains bound to the endo-
thelium after transcytosis, similarly to what was reported
for the chemokine CXCL8 (Middleton et al., 1997). It is
conceivable that in this formHP-NAP comes in contact with
rolling neutrophils and monocytes and promotes the up-
regulation of b2 integrin expression on their surface (Satin
et al., 2000). b2 Integrins, which are crucial for the tight
adhesion of leukocytes to the endothelium before extrav-
asation, need also to be activated to acquire their ligand-
binding capacity. Again HP-NAP shows a role since it
induces a conformational change of b2 integrins, resulting
in an increased affinity for the endothelial partner (Polen-
ghi et al., 2007). Collectively these data suggest that HP-
NAP, via its direct intervention, has a crucial role in
recruiting leukocytes towards the infected area and
therefore, in triggering the inflammation process. Further-
more, HP-NAP stimulates mast cells and macrophages to
release TNF-a (Montemurro et al., 2001; Amedei et al.,
2006). TNF-a is a pleiotropic cytokine which increases the
adhesiveness of endothelial cells by up-regulating adhe-
sionmolecules, such as V-CAM and I-CAM (Silverstein et al.,
2000). Moreover TNF-a can induce activation of integrins
on PMN, directly or via CXCL8 whose endothelial secretion
is stimulated by TNF-a (Laudanna et al., 2002; Gamble
et al., 1985). Thus, HP-NAP, both alone and together with
other host-derived factors, triggers in vivo the PMN accu-
mulationwithin the tissue, evoking the adhesive properties
of PMN and endothelium. In addition, considering that
recruited PMN release cytokines and chemokines and that,
under HP-NAP stimulation, they release TNF-a, CXCL8,
CCL3 and CCL4, PMN may contribute to the generation of
the condition required for the recruitment of additional
neutrophils, monocytes and lymphocytes (Polenghi et al.,
2007). Although it is undoubted that HP-NAP plays a major
role in PMN recruitment and activation, other bacterial
factors are also important (Unemo et al., 2005). The
acronym HP-NAP was originally attributed to the H. pylori
dodecameric bacterioferritin because of its ability to induce
neutrophils to produce reactive oxygen radicals (ROI)(Evans et al., 1995). Such a property has been further
documented by Satin et al. (2000) and Wang et al. (2008),
the latter also showing that HP-NAP promotes the release
of myeloperoxidase from human neutrophils. It has been
reported that the ability of HP-NAP in inducing the release
of oxygen radicals is exerted also on monocytes and
depends on the activation of the NADPH oxidase. HP-NAP
acts through a cascade of intracellular activation events,
which is completely prevented by pertussis toxin: it
includes the increment of cytosolic Ca2þ and the phos-
phorylation of proteins, leading to the assembly of active
NADPH oxidase on the neutrophil plasmamembrane (Satin
et al., 2000; Montecucco and Rappuoli, 2001). The pattern
of events triggered by HP-NAP is closely similar to that
triggered by heptahelical receptors specific for the
chemotactic agonist fMLP, C5a, platelet activating factor
(PAF), and CXCL8 (Rossi et al., 1985; Thelen et al., 1993).
Such similarity strongly suggests that one possible HP-NAP
receptor is a G-coupled heptahelical protein receptor, still
to be identified (Nishioka et al., 2003).
3. Effects of HP-NAP on monocytes
HP-NAP efficiently stimulates human monocytes to
synthesize tissue factor (TF) and plasminogen activator
inhibitor-2 (PAI-2) (Montemurro et al., 2001). Conse-
quently, the procoagulant potential of monocytes increases
while their fibrinolytic capacity decreases, tilting therefore
the cell coagulation–fibrinolysis balance towards fibrin
formation and pro-thrombotic events. This action of HP-
NAP is expected to favor chronic development of gastritis
and tissue disruption by hampering tissue healing, which
requires degradation and removal of fibrin and tissue
debris. At the same time, fibrin deposition might hinder
movement of phagocytes towardsH. pylori cells and protect
them from phagocytosis (Montemurro et al., 2001).
Stimulation of monocytes and dendritic cells (DC) by
HP-NAP results also in a prompt and remarkable up-regu-
lation of cytokines including IL-12p35 and IL-12p40, which
pair to form the active IL-12 molecule, and IL-23p19 which
assembles with the IL-12p40 chain to form the IL-23 het-
erodimer (Amedei et al., 2006). In other words HP-NAP
induces an IL-12- and IL-23-enriched milieu, which has the
potential to drive the differentiation of antigen-stimulated
T cells towards the Th1 phenotype (Oppmann et al., 2000;
Trinchieri, 2003) (Fig. 1).
The unique role of HP-NAP with regard to the whole
bacterium was better specified by comparing HP-NAP-null
H. pylori mutant with the wild-type bacterium for the
efficiency in inducing monocyte cytokine synthesis. Both
wild-type and HP-NAP-null mutant bacteria were able to
induce the production of comparable amounts of TNF-a, IL-
6, and IL-8 by monocytes. In contrast, stimulation with the
highest dose of HP-NAP-null mutantH. pylori (5105 CFUs/
ml) resulted in very poor secretion of IL-12, which was
lower than that induced by a 25 times lower concentration
of wild-type H. pylori (0.2105 CFUs/ml). These data
suggest that a number of H. pylori components can activate
monocytes to cytokine synthesis, but HP-NAP represents
the critical molecule for the induction of substantial IL-12
secretion (Amedei et al., 2006).
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strong up-regulation of Th1-polarizing cytokines, TF and
PAI-2 production, but also in the induction of a progressive
maturation of monocytes into mature dendritic cells
showing high expression of HLA-DR, CD80 and CD86,
longer survival, and a tendency to cluster and to detach
from the substrate (Amedei et al., 2006). A previous study
showed that H. pylori induces dendritic cells to release IL-6,
IL-8 and IL-12, and represents a maturation stimulus for
human DC (Kranzer et al., 2004). However, the bacterial
factor responsible for such effects was not identified: HP-
NAP might represent that factor, due to its ability to mimic
all the effects induced by H. pylori. Interestingly, the
immune modulating activity of HP-NAP does not result
from the engagement of a G-coupled heptahelical receptor,
rather it is triggered by the activation of the toll-like
receptor 2 (TLR-2) (Nishioka et al., 2003; Amedei et al.,
2006).
4. HP-NAP and gastric Th1-polarized response
In infectious diseases, T helper cells (Th) orchestrate the
host defense against pathogens via various types of cyto-
kines and effector functions. Th1 cells produce IFN-g and
TNF-b, and elicit macrophage activation and TF production,
whereas Th2 cells produce IL-4, IL-5 and IL-13, and inhibit
several macrophage functions, including TF synthesis
(D’Elios and Del Prete, 1998). Th0 cells do not express
a polarized Th1 or Th2 profile, and represent a population
of effector cells secreting different combinations of Th1 and
Th2 cytokines. In H. pylori infection, a predominant acti-
vation of Th1 cells with production of IFN-g and increased
expression of IL-12, IL-18, IL-17 and TNF-a occurs in vivo in
the antrum (D’Elios et al., 1997; Bamford et al., 1998; Luzza
et al., 2000; Tomita et al., 2001; Lehmann et al., 2002). In
the gastric mucosa of H. pylori-infected patients a remark-
able proportion of Th cells showed significant proliferation
in response to different H. pylori antigens, including HP-
NAP (D’Elios et al., 1997; Amedei et al., 2006). Upon HP-NAP
stimulation, antigen-specific gastric Th cells produced large
amounts of IFN-g and TNF-a and displayed a powerful
cytotoxic activity, thus showing a polarized Th1 effector
phenotype (Amedei et al., 2006). Collectively, these results
demonstrate that there is a strict correlation between in
vitro and in vivo effects of HP-NAP and they define the
bacterial protein as responsible for driving the Th1
response in the gastric antrum of patients affected by H.
pylori (Fig. 1).
5. Effect of HP-NAP on lymphocytes: Th1 induction
and Th2 down-modulation
Consistent with the ability to trigger the secretion of
important Th1 inducers, such as IL-12 and IL-23, HP-NAP
was found able to modulate in vitro the cytokine profile of
human T cell response, towards the Th1 profile. Indeed, by
conditioning T cell cultures with HP-NAP a remarkable
increase of IFN-g-producing cells and a decrease of IL-4-
secreting cells were observed. This cytokine profile of
antigen-specific Th cells, generated in the presence or
absence of HP-NAP, was evaluated at clonal level, usingtetanus toxoid (TT) and mite allergens as antigen. The
results obtained in the case of mite allergen were particu-
larly interesting because Th cell responses to allergens are
usually definitely oriented to the Th2 pattern. In the series
of allergen-specific Th clones, not conditioned with HP-
NAP, 1% of clones were Th1, 10% were Th0 (cells producing
either IFN-g and IL-4), and 89% were Th2. In contrast, in the
series of allergen-specific Th clones conditioned with HP-
NAP, Th1 and Th0 clones accounted for 38% and 33%,
respectively, and Th2 clones accounted for only 29%. In
other words, addition in culture of HP-NAP resulted in
a shift from preferential Th2 to predominant Th1 T cell
responses, with a remarkable increase of IFN-g producing T
cell clones and a strong reduction of allergen-specific
clones with the Th2 profile. Interestingly, the majority of
allergen-specific Th cell clones obtained upon HP-NAP
conditioning displayed strong cytolytic activity, suggesting
that the Th1-immune modulatory effect of HP-NAP not
only affects the T cell cytokine production, but also triggers
the expression of the cytotoxic program, a property of the
fully Th1-polarized effector T cells (D’Elios and Del Prete,
1998; Amedei et al., 2006). Of note, HP-NAP had a strong
Th1-polarizing effect also on non-allergen-specific
(bystander) Th clones that were grown in the context of
allergen-induced T cell lines (Amedei et al., 2006; D’Elios
et al., 2009).
6. HP-NAP exerts a powerful anti-Th2 activity in vivo
Although in vitro experiments carried on allergen-
induced T cell lines generated from mononuclear cells of
house dust mite allergen-sensitive donors represented
a strong evidence for the Th1-promoting and Th2-inhib-
iting activity of HP-NAP, the first evidence that the bacte-
rial protein was capable of redirecting Th2 responses
towards the Th1 phenotype came from two recent reports
(Codolo et al., 2008a; Del Prete et al., 2008). In both studies
HP-NAP was applied in vivo to a Th2-dominated animal
model, such as mice affected by allergic asthma in the
former study and mice infected with Trichinella spiralis (Ts)
in the latter.
The study carried out by Codolo et al. (2008a) was based
on a mouse model of allergic asthma induced by inhaled
ovalbumin (OVA) (Gonzalo et al., 1996). After intra-perito-
neal priming followed by repeated aerosol challenge with
OVA, Th2 responses were induced in the mouse lung,
resulting in eosinophils recruitment in bronchial airways
and serum IgE levels increment. In this study, HP-NAP was
administered simultaneously with OVA priming, by intra-
peritoneal injection, or via intranasal instillation 7 day after
the phase of sensitization. Both systemic and mucosal
administration of HP-NAP strongly inhibited the develop-
ment of airway eosinophilia and bronchial inflammation
and led to reduction of total serum IgE and to increase of IL-
12 plasma levels (Codolo et al., 2008a).
IgE hyper-production and eosinophilia are typical
immune responses evoked by Ts. Eosinophilia is due to the
selective induction and expansion of Th2 cells that produce
IL-5 and the high IgE response is due to the concomitant
production of IL-4 and IL-13, which are key molecules for
differentiation of B cell to IgE-producing cells (Mosmann
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2000). Treatment with HP-NAP of mice with established Ts
infection resulted in a strong anti-Th2 effect, as demon-
strated by reduced eosinophilia and lower levels of total IgE
in comparison with control animals. In addition, evidence
was provided that HP-NAP in vivo resulted in ongoing
production of endogenous IL-12 and IFN-g even days after
its delivery, as well as in persistent inhibition of the Ts-
induced expression of IL-4 and IL-5 (Del Prete et al., 2008).
Interestingly, both in vivo studies demonstrate that the
binding of HP-NAP to the TLR-2 is crucial for the bacterial
protein to exert its anti-Th2 activity.
7. Concluding remarks
In H. pylori infection the bacterium induces an inflam-
matory response in the gastric mucosa, characterized by
polymorphonuclear and mononuclear cell infiltration. A
key factor in orchestrating the recruitment and activation
of these cells is HP-NAP, which not only directly promotes
the accumulation of inflammatory cells within the infected
gastric tissue but also activates them to release pro-
inflammatory cytokines and chemokines, that contribute to
the maintenance of the flogistic process. Notably, HP-NAP
stimulates neutrophils and monocytes to release IL-12 and
IL-23, the two pivotal cytokines responsible for driving the
Th response towards the Th1 phenotype. This T cell subset
is the most represented in the stomach of H. pylori-infected
individuals and is associated with more serious diseases.
Indeed, Th1 cells, by producing large amounts of IFN-g and
by activating a cytolytic cascade strongly contribute to
gastric damage. Moreover, high levels of TF, which is also
induced by HP-NAP, IFN-g and TNF-a, might result in pro-
coagulant activity and in an increment of gastric secretion
and of pepsinogen release. The ability of HP-NAP to shift
a Th response towards the Th1 phenotype has been clearly
documented in vivo: in the gastric mucosa of H. pylori-
infected patients a remarkable proportion of Th cells show
significant proliferation to different H. pylori antigens,
including HP-NAP. Upon HP-NAP stimulation, antigen-
specific gastric Th cells produce high amounts of IFN-g and
TNF-a.
Epidemiological studies and experimental data
provided evidence of an inverse association between H.
pylori infection and the frequency of allergic asthma (Blaser
et al., 2008); however, the absence of a convincing molec-
ular mechanism represented a limitation of this study and
raised several criticisms. In virtue of its striking immune
modulating activity, HP-NAPmight be part of themolecular
mechanism underlying such a negative association. Most
importantly, the capacity of HP-NAP in inhibiting Th2
responses in vitro and in vivo in allergic bronchial asthma,
in humans and mice, makes this bacterial protein an
important candidate for novel strategies of prevention and
treatment of asthma and allergic diseases. Furthermore,
considering that HP-NAP is a very powerful inducer of IL-12
and that IL-12 represents the most effective cytokine in
terms of tumor eradication, anti-metastatic activity and
long-term anti-tumor immunity, it is tempting to speculate
that HP-NAP might be beneficial not only against allergic
disease but also to fight cancer, e.g. as adjuvant for localimmunotherapy of some neoplasias (Colombo and Trin-
chieri, 2002; Trinchieri, 2003; D’Elios et al., 2007).
Noteworthy, HP-NAP shares significant homology with
other Dps-like proteins, produced by bacteria associated
with chronic inflammation, such as NapA of Borrelia burg-
dorferi (Li et al., 2007; Codolo et al., 2008b): also this
protein is endowed of specific immune modulatory prop-
erties, although different from those ascribed to HP-NAP. In
fact, NapA is able to drive the expression of IL-6, IL-1, IL-23,
and TGF-b by cells of the innate immune system and to
elicit a synovial fluid Th17 cell response that might play
a crucial role in the pathogenesis of Lyme arthritis (Codolo
et al., 2008b).
In conclusion, HP-NAP emerges as the prototype of
a novel class of Dps-like proteins, characterized by the
ability of driving and orchestrating the inflammation
associated with bacterial infections. From this point of view
it could be considered as ‘‘foe’’ because of its contribution
to the tissue damage associated with the flogistic process.
However, in virtue of its immune modulatory properties it
should also be seen as a promising and ‘‘friendly’’ ther-
apeutical tool.
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